MedTrace Logo

Biomarkers of Bone Resorption in Metastatic Prostate Cancer

NCT01233557 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2015-11-05

No results posted yet for this study

Summary

Biomarkers of bone resorption will be measured in the blood of patients with bone metastases from prostate cancer during the course of their illness. Changes in these biomarkers will be correlated with the patient's treatment with antiandrogen therapy and bisphosphonates and the response and/or progression of their cancer. It is hoped that serial measurement of these biomarkers may allow therapeutic monitoring in the future with successful individualisation of bisphosphonate therapy for metastatic prostate cancer.

Conditions

Sponsors & Collaborators

  • University of Aberdeen

    lead OTHER

Principal Investigators

  • Donald Bissett, M.D. · NHS Grampian

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01233557 on ClinicalTrials.gov